Trial Code
Ages
Location
Gender
Ethnicity
Payment
Nicotine Restrictions
Duration of stay
Summary
- We are conducting a clinical trial for a new investigational drug that could be used to treat people with alpha-1 antitrypsin deficiency (AATD) with PiZZ genotype. The drug is considered ‘investigational’ as it is not yet approved by any public health authority for any kind of treatment.
- We are recruiting male and female participants aged over 18 and less than 75 years old with AATD with PiZZ genotype.
- The clinical trial involves having a single dose or multiple doses of the investigational drug as an injection under the skin in your abdomen, thigh or arm.
- The trial will help us to determine how safe and tolerable the drug is, how long the drug stays in the body, and how the drug affects the body.
- You will be reimbursed for your time if you take part in this clinical trial.
If you are interested in participating in this participant engagement study (part A):
- You will need to attend a screening appointment at our clinical research unit so we can check if you are suitable to take part in the trial. At this appointment, we will perform several assessments, including but not limited to taking blood, checking your heart function, and carrying out a physical examination
- If results from your screening appointment show you are suitable for the trial, you will be invited to take part
- The trial will involve:
- An in-house stay of 3 days / 2 nights in our clinical research unit. During your stay, you will receive a single dose of investigational drug as injection(s) under the skin in your abdomen, thigh or arm and be closely monitored for safety. There will also be several assessments (like those at screening) conducted to check how safe and tolerable the drug is, how long the drug remains in your body, and how the drug affects your body.
- After discharge, you will be required to return for 10 follow-up appointments.
- Participation in Part A of the trial will last approximately 55 weeks, with at least 12 visits to the clinical research unit. However, your participation in the trial may be longer depending on how your body responds to the investigational drug.
Who can take part?
We will check your suitability for the study using the following criteria:
- You are aged over 18 and less than 75 years old.
- You weigh between 45 kg and 110 kg (inclusive) and have a Body Mass Index (BMI) between 18 and 33 kg/m2.
- You must have been diagnosed with alpha-1 antitrypsin deficiency (AATD) and have the PiZZ genotype.
- Are a non-smoker, including vaping, for a least 6 months prior to screening.
- You must not have received AAT therapy within 30 days prior to screening.
- You must not have had a respiratory tract infection that required treatment within 8 weeks prior to dosing.
A full list of do’s and don’ts will be given to you by a member of our recruitment team if you are interested.
In recognition of the time involved in taking part in the trial, you will receive £6,625 (£75 screening payment, £4,367 clinical trial payment and £2,187 compliance bonus) on completion of the clinical trial, provided you comply fully with all the clinical trial requirements. This amount is based on the anticipated clinical trial plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Contact Us
Email: volunteer@richmondpharmacology.com
Call us: Mon - Fri between 09h00 and 17h00 on +44 (0) 207 042 5802 to speak to a member of our Volunteer Recruitment Team.
Approval
Any response to this advertisement will be recorded. Your response will not place you under and obligation to participate in this study.
Ref: Ref: C25018_Feb-2026 (email_website_advert text)
